AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs
BioSpace
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
pharminent
May 18, 2026 (Last updated: May 18, 2026)
BioSpace
Baxfendy, the first aldosterone synthase inhibitor to be approved by the FDA for high blood pressure, is among the products AstraZeneca is relying on to hit its 2030 goal of $80 billion in revenue.
